BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PYVOBJECT//NONSGML Version 1//EN
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:STANDARD
DTSTART:20001029T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20000326T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:20260725T085313Z - 89329@eupv304
DTSTART;TZID=Europe/Brussels:20261128T083000
DTEND;TZID=Europe/Brussels:20261128T140000
CREATED:20260725T085313Z
DESCRIPTION:BELSACI SYMPOSIUM 2026\nBELSACI SYMPOSIUM 2026 Organized b
y the Belgian Society for Allergy and Clinical Immunology (BELSACI) Saturd
ay\, 28 November 2026\, at The Faculty Club\, Leuven\, from 8:30 a.m. to 2
p.m. The main topic will be ANAPHYLAXIS. Come to discover our new innovat
ive solutions in the field of allergy research:A Next-Generation Basophil
Activation Test (BAT) for research use only to more effectively characteri
ze food allergies without exposure to potentially harmful allergens. Appro
ximately 220 million people globally suffer from at least one food allergy
. Most food allergies and treatment efficacies are currently determined th
rough a dated and rigorous Oral Food Challenge (OFC)\, exposing a patient
to gradual amounts of foods to determine if they have a reaction\, which c
ould include anaphylaxis in some situations. The new BAT test eliminates t
hat risk\, testing for multiple allergens at once through a blood draw --
saving hours of food testing and exposure to potentially harmful reactions
. This offers a groundbreaking alternative in allergy testing\, removing p
atient obstacles and reducing ethical concerns associated with direct alle
rgen exposure in vulnerable participants\,” Jean-Marc Busnel\, PhD\, Pri
ncipal Investigator and Senior Staff Research Scientist\, Beckman Coulter
Life Sciences “For too long these concerns have limited critical advance
ments\, putting people at risk of not having access to life-saving treatme
nt options should an allergic reaction occur. By removing these barriers\,
this test unlocks an opportunity to finally expand food allergy drug deve
lopment and research. This reinforces our mission at Beckman Coulter Life
Sciences to deliver tools that empower clinicians and improve patient outc
omes.” The innovation follows the FARE (Food Allergy Research and Educat
ion) Innovation Award Diagnostic Challenge which Beckman Coulter Life Scie
nces received in 2022. The $1 [...]
DTSTAMP:20260725T085313Z
LOCATION:Groot Begijnhof 14\, 3000 Leuven\, Belgium
SUMMARY:BELSACI SYMPOSIUM 2026
X-ALT-DESC;FMTTYPE=text/html:BELSACI SYMPOSIUM 2026\nBELSACI SYMPOSIUM
2026 Organized by the Belgian Society for Allergy and Clinical Immunology
(BELSACI) Saturday\, 28 November 2026\, at The Faculty Club\, Leuven\, fr
om 8:30 a.m. to 2 p.m. The main topic will be ANAPHYLAXIS. Come to discove
r our new innovative solutions in the field of allergy research:A Next-Gen
eration Basophil Activation Test (BAT) for research use only to more effec
tively characterize food allergies without exposure to potentially harmful
allergens. Approximately 220 million people globally suffer from at least
one food allergy. Most food allergies and treatment efficacies are curren
tly determined through a dated and rigorous Oral Food Challenge (OFC)\, ex
posing a patient to gradual amounts of foods to determine if they have a r
eaction\, which could include anaphylaxis in some situations. The new BAT
test eliminates that risk\, testing for multiple allergens at once through
a blood draw -- saving hours of food testing and exposure to potentially
harmful reactions. This offers a groundbreaking alternative in allergy tes
ting\, removing patient obstacles and reducing ethical concerns associated
with direct allergen exposure in vulnerable participants\,” Jean-Marc B
usnel\, PhD\, Principal Investigator and Senior Staff Research Scientist\,
Beckman Coulter Life Sciences “For too long these concerns have limited
critical advancements\, putting people at risk of not having access to li
fe-saving treatment options should an allergic reaction occur. By removing
these barriers\, this test unlocks an opportunity to finally expand food
allergy drug development and research. This reinforces our mission at Beck
man Coulter Life Sciences to deliver tools that empower clinicians and imp
rove patient outcomes.” The innovation follows the FARE (Food Allergy Re
search and Education) Innovation Award Diagnostic Challenge which Beckman
Coulter Life Sciences received in 2022. The $1 [...]
END:VEVENT
END:VCALENDAR